Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 100 peer-reviewed journal articles Updated
Oncology · Pancreatic Neuroendocrine Tumor

Understanding Your pNET Diagnosis

At a Glance

A pancreatic neuroendocrine tumor (pNET) is a rare, slow-growing tumor starting in the hormone-producing cells of the pancreas. It is entirely different from typical pancreatic cancer, generally having a much better prognosis and highly specialized treatment options rather than standard chemo.

Receiving a diagnosis involving the pancreas often triggers immediate fear because most people associate it with the more common and aggressive form of pancreatic cancer. It is important to take a deep breath and look closely at your pathology report. If you have been diagnosed with a pancreatic neuroendocrine tumor (pNET), you are dealing with a disease that is biologically and clinically distinct from the “typical” pancreatic cancer you may have heard about [1][2].

While both occur in the same organ, a pNET is not the same as pancreatic ductal adenocarcinoma (PDAC) [1]. Understanding these differences is the first step in moving from a state of panic to a state of focused management.

Understanding the Difference

The pancreas has two main jobs: producing digestive enzymes and producing hormones. Most pancreatic cancers (about 95%) start in the ducts that carry enzymes and are called PDAC [1]. In contrast, pNETs begin in the hormone-producing cells, known as the islets of Langerhans [2].

Because they start in different cells, these two types of tumors behave very differently. A pNET is a rare diagnosis, representing less than 5% of all pancreatic tumors [1]. This rarity is one reason why it is essential to be seen by a specialist who focuses specifically on neuroendocrine tumors (NETs), often found at NCI-designated cancer centers or through NET research foundations. The treatment paths for pNETs are highly specialized [3][4].

Three Stabilizing Facts

When processing this news, keep these three research-backed facts in mind to help ground your perspective:

  1. Slower Growth (Indolent Behavior): Many pNETs are indolent, meaning they grow much more slowly than typical pancreatic cancer [5][6]. While PDAC is known for rapid progression, some pNETs can remain stable for long periods, sometimes even allowing for a “watch and wait” approach called active surveillance for small, low-grade tumors [5][7].
  2. Better Long-Term Outlook: Patients with pNETs generally have a significantly more favorable prognosis (expected outcome) and higher survival rates than those with PDAC [1][8]. Because these tumors are often less aggressive, doctors have more time to carefully plan a multi-step treatment strategy [9][10].
  3. Diverse Treatment Options: pNETs have a wide range of effective treatments. These include somatostatin analogs (hormone-balancing injections), targeted therapies, pNET-specific oral chemotherapies, and advanced nuclear medicine like PRRT (Peptide Receptor Radionuclide Therapy) [3][11][12].

Why Differentiation Matters

Your doctors will use specialized tools to confirm your diagnosis and “grade” your tumor. They look for specific biomarkers like chromogranin A, which are often present in pNETs but not in other pancreatic cancers [13]. They also use advanced imaging, such as Ga-68 DOTATATE PET scans, which can “light up” pNET cells specifically [14][15].

Knowing exactly what you are fighting allows your care team to use the right tools for a pNET. This typically means avoiding the standard cell-killing (cytotoxic) IV chemotherapy regimens required for PDAC, and instead utilizing specialized treatments tailored to neuroendocrine biology [3][16]. While any diagnosis is serious, a pNET diagnosis opens a different door—one that often involves years of management and a focus on maintaining a high quality of life [6][17].

In this guide

6 chapters

01

Symptoms & Subtypes: Functional vs. Non-Functional pNETs

Learn the difference between functional and non-functional pancreatic neuroendocrine tumors (pNETs). Understand hormone symptoms and mass-effect signs.

02

Decoding Your Pathology Report

Learn how to read your pancreatic neuroendocrine tumor (pNET) pathology report. Understand Ki-67 index, WHO grading, mitotic rate, and what they mean for you.

03

How pNETs are Found and Evaluated

Learn how pancreatic neuroendocrine tumors (pNETs) are diagnosed. Understand the timeline, EUS-FNB biopsies, and why Ga-68 DOTATATE PET/CT scans are used.

04

Standard of Care Treatment Options

Learn about standard treatment options for pancreatic neuroendocrine tumors (pNETs), including active surveillance, surgery, CAPTEM, and PRRT (Lutathera).

05

Genetics & Hereditary Syndromes

Learn how genetics and hereditary syndromes like MEN1 and VHL affect pancreatic neuroendocrine tumors (pNETs), including genetic testing and treatment options.

06

Monitoring and Life After Treatment

Learn what to expect after pNET treatment. Understand your surveillance schedule, managing digestion with PERT, Chromogranin A tests, and recurrence options.

Common questions in this guide

How is a pNET different from typical pancreatic cancer?
A pNET starts in the hormone-producing cells of the pancreas, while typical pancreatic cancer (PDAC) starts in the digestive ducts. pNETs are generally slower-growing, less aggressive, and have a better long-term prognosis.
What does it mean if my pNET is indolent?
An indolent tumor grows very slowly. Because of this slow growth, some small, low-grade pNETs can be monitored closely with a watch-and-wait approach called active surveillance instead of requiring immediate treatment.
What treatments are available for pNETs?
Treatment options are specialized and do not usually involve standard IV chemotherapy. They can include hormone-balancing injections called somatostatin analogs, targeted therapies, oral chemotherapies, and advanced nuclear medicine like PRRT.
What is a Ga-68 DOTATATE PET scan?
This is an advanced imaging test specifically designed to find and highlight neuroendocrine tumor cells. It helps your doctors accurately map the tumor's location to plan the most effective specialized treatment.
Why is it important to see a specialist for a pNET?
Because pNETs account for less than 5% of all pancreatic tumors, they require highly specialized diagnostic tools and distinct treatment paths. A neuroendocrine specialist has the specific expertise needed to manage this rare disease effectively.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you confirm my diagnosis is a pancreatic neuroendocrine tumor (pNET) and not pancreatic ductal adenocarcinoma (PDAC)?
  2. 2.What is the grade (G1, G2, or G3) and Ki-67 index of my tumor?
  3. 3.Is my tumor 'functional' or 'non-functional,' and how does that affect my symptoms?
  4. 4.How many pNET patients does this hospital treat each year, and do we have a neuroendocrine specialist on the team?
  5. 5.What specific imaging (like a Ga-68 DOTATATE PET scan) do I need to accurately map this tumor?
  6. 6.Will my case be discussed at a Multidisciplinary Tumor Board that specializes in neuroendocrine tumors?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Islet Cell Tumors of the Pancreas.

    Amin S, Kim MK

    Gastroenterology clinics of North America 2016; (45(1)):83-100.

    PMID: 26895682
  2. 2

    Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration.

    Greenberg J, Limberg J, Verma A, et al.

    JCI insight 2022; (7(23)).

    PMID: 36301668
  3. 3

    Neuroendocrine Neoplasms: Epidemiology, Diagnosis, and Management.

    Ramesh A, Chatterjee A, Subramaniam RM

    PET clinics 2023; (18(2)):161-168 doi:10.1016/j.cpet.2022.10.002.

    PMID: 36707369
  4. 4

    mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).

    Zanini S, Renzi S, Giovinazzo F, Bermano G

    Frontiers in endocrinology 2020; (11()):562505 doi:10.3389/fendo.2020.562505.

    PMID: 33304317
  5. 5

    Nonfunctioning Incidental Pancreatic Neuroendocrine Tumors: Who, When, and How to Treat?

    Gorelik M, Ahmad M, Grossman D, et al.

    The Surgical clinics of North America 2018; (98(1)):157-167 doi:10.1016/j.suc.2017.09.014.

    PMID: 29191272
  6. 6

    Pancreatic islet cell tumors in adolescents and young adults.

    Waters AM, Maizlin II, Russell RT, et al.

    Journal of pediatric surgery 2019; (54(10)):2103-2106 doi:10.1016/j.jpedsurg.2019.01.060.

    PMID: 30954230
  7. 7

    Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

    Tanaka M, Heckler M, Mihaljevic AL, et al.

    Annals of surgical oncology 2021; (28(3)):1614-1624 doi:10.1245/s10434-020-08850-7.

    PMID: 32720049
  8. 8

    SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018).

    González-Flores E, Serrano R, Sevilla I, et al.

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2019; (21(1)):55-63 doi:10.1007/s12094-018-1980-7.

    PMID: 30535553
  9. 9

    The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia.

    Inzani F, Petrone G, Rindi G

    Endocrinology and metabolism clinics of North America 2018; (47(3)):463-470 doi:10.1016/j.ecl.2018.04.008.

    PMID: 30098710
  10. 10

    Surgical Management of Pancreatic Neuroendocrine Tumors.

    Clancy TE

    Hematology/oncology clinics of North America 2016; (30(1)):103-18.

    PMID: 26614371
  11. 11

    Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?

    Hope TA, Pavel M, Bergsland EK

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(24)):2818-2829 doi:10.1200/JCO.22.00176.

    PMID: 35649195
  12. 12

    Metastatic VIPoma, Cosecreting Insulin, With Complete Response to Lanreotide, Capecitabine, and Temozolomide.

    Marques B, Monteiro AR, Martins RG, et al.

    Pancreas 2020; (49(3)):e19-e20 doi:10.1097/MPA.0000000000001514.

    PMID: 32168252
  13. 13

    Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute.

    Jun E, Kim SC, Song KB, et al.

    Surgery 2017; (162(1)):120-130 doi:10.1016/j.surg.2017.01.019.

    PMID: 28262254
  14. 14

    [68Ga]-DOTATOC PET/CT Volumetric Parameters Reflect Metastatic Potential in Pancreatic Neuroendocrine Tumors.

    Kim SJ, Cha J, Lee HS, et al.

    Cancers 2025; (17(9)) doi:10.3390/cancers17091487.

    PMID: 40361414
  15. 15

    State-of-the-art Imaging of Pancreatic Neuroendocrine Tumors.

    Tamm EP, Bhosale P, Lee JH, Rohren EM

    Surgical oncology clinics of North America 2016; (25(2)):375-400.

    PMID: 27013371
  16. 16

    Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

    Strosberg J, El-Haddad G, Wolin E, et al.

    The New England journal of medicine 2017; (376(2)):125-135 doi:10.1056/NEJMoa1607427.

    PMID: 28076709
  17. 17

    The prognostic impact of primary tumor resection in pancreatic neuroendocrine tumors with synchronous multifocal liver metastases.

    Lin C, Dai H, Hong X, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2018; (18(5)):608-614 doi:10.1016/j.pan.2018.04.014.

    PMID: 29731245

This page is for informational purposes only and does not replace professional medical advice. Always consult your oncology team or a neuroendocrine specialist regarding your specific pNET diagnosis and treatment options.

Get notified when new evidence is published on Neuroendocrine tumor of pancreas.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.